

# Produktinformation



Forschungsprodukte & Biochemikalien
Zellkultur & Verbrauchsmaterial
Diagnostik & molekulare Diagnostik
Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

## SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 F. +43(0)1 489 3961-7 <u>mail@szabo-scandic.com</u> www.szabo-scandic.com

## BMS-345541

Cat. No.:	HY-10519		
CAS No.:	445430-58-	0	
Molecular Formula:	C <sub>14</sub> H <sub>17</sub> N <sub>5</sub>		
Molecular Weight:	255.32		
Target:	IKK		
Pathway:	NF-κB		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

#### SOLVENT & SOLUBILITY

In Vitro	DMSO : 10 mg/mL (39.17 mM; Need ultrasonic) H <sub>2</sub> O : 10 mg/mL (39.17 mM; ultrasonic and warming and heat to 60°C)						
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	3.9167 mL	19.5833 mL	39.1665 mL		
		5 mM	0.7833 mL	3.9167 mL	7.8333 mL		
		10 mM	0.3917 mL	1.9583 mL	3.9167 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (3.92 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-B-CD in saline) Solubility: $\ge 1 \text{ mg/mL}$ (3.92 mM); Clear solution						
	<ol> <li>Add each solvent</li> <li>Solubility: ≥ 1 mg/</li> </ol>	one by one: 10% DMSO >> 90% cor mL (3.92 mM); Clear solution	n oil				

	ту	١					
BIOLOGICAL ACTIV		/					
Description		^	<b>FF 41</b> is a sale stine in hi				
Description	BMS-34	1	5541 is a selective inhi	5541 is a selective inhibitor of the catalytic su	5541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2	5541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC <sub>50</sub> =0.3 $\mu$ M, IKK	5541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC <sub>50</sub> =0.3 $\mu$ M, IKK-1 IC <sub>50</sub> =4 $\mu$ M). BM
	an allos	ste	eric site of IKK.	eric site of IKK.	eric site of IKK.	eric site of IKK.	eric site of IKK.

 IC<sub>50</sub> & Target
 IKK-2
 IKK-1

 0.3 μM (IC<sub>50</sub>)
 4 μM (IC<sub>50</sub>)

N H NH<sub>2</sub>



In Vitro	BMS-345541 selectively inhibits the stimulated phosphorylation of I $\kappa$ B $\alpha$ in cells (IC <sub>50</sub> =4 $\mu$ M). Consistent with the role of IKK/NF- $\kappa$ B in the regulation of cytokine transcription, BMS-345541 inhibits lipopolysaccharide-stimulated tumor necrosis factor $\alpha$ , interleukin-1 $\beta$ , interleukin-8, and interleukin-6 in THP-1 cells with IC <sub>50</sub> values in the 1 to 5 $\mu$ M range <sup>[1]</sup> . BMS-345541 treatment results in a concentration-dependent inhibition of melanoma cell proliferation in SK-MEL-5, A375, and Hs 294T cells. BMS-345541 (0, 100 $\mu$ M) shows apoptotic features as revealed by TUNEL staining and nuclear condensation <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	BMS-345541 (10 mg/kg, p.o.) results in prolonged serum drug levels, with concentrations sustained at or above 1 μM for many hours in mice. BMS-345541 dose-dependently inhibits the production of TNFα measured in the serum of animals challenged with an intraperitoneal administration of LPS <sup>[1]</sup> . BMS-345541 (0, 10, 25, and 75 mg/kg, p.o.) effectively inhibits SK-MEL-5 tumor growth in a dose-dependent manner in the mice. Tumor-bearing mice treated with 75 mg/kg of BMS-345541 show effective inhibition of growth of SK-MEL-5, A375, and Hs 294T tumors by 86±2.8%, 69±11% and 67±3.4%, respectively <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### PROTOCOL

Kinase Assay <sup>[1]</sup>	Assays measuring the enzyme-catalyzed phosphorylation of GST-IκBα are performed by adding enzyme (IKK-2, IKK-1, or IKK-ε, typically to a final concentration of 0.5 µg/mL) at 30°C to solutions of 100 µg/mL GST-IκBα and 5 µM [ <sup>33</sup> P]ATP in 40 mM Tris-HCl, pH 7.5, containing 4 mM MgCl <sub>2</sub> , 34 mM sodium phosphate, 3 mM NaCl, 0.6 mM potassium phosphate, 1 mM KCl, 1 mM dithiothreitol, 3% (w/v) glycerol, and 250 µg/mL bovine serum albumin. The specific activity of [ <sup>33</sup> P]ATP used in the assay is 100 Ci/mmol. After 5 min, the kinase reactions are stopped by the addition of 2× LaemmLi sample buffer and heat-treated at 90°C for 1 min. The samples are then loaded on to NuPAGE 10% BisTris gels. After completion of SDS-PAGE, gels are dried on a slab gel dryer. The bands are then detected using a 445Si PhosphorImager, and the radioactivity is quantified using ImageQuant software. Under these conditions, the degree of phosphorylation of GST-IκBα is linear with time and concentration of enzyme <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay <sup>[2]</sup>	SK-MEL-5 cells are treated with BMS-345541 at different concentrations (0, 1.0, 10, and 100 μM) for different time periods. The cells are collected by trypsinization, fixed in 70% ethanol for 2 hours on ice and stained with PI solution (PBS containing 2 μg/mL PI, 0.1% Triton X-100, and 125 units/mL RNase A) at 37°C for 30 minutes. Cell fluorescence is measured by flow cytometry with 488 nm excitation and 620 nm emission filters and resulting data are analyzed using the software program MultiCycle <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration <sup>[1]</sup>	Mice <sup>[1]</sup> BMS-345541 is administered either by intravenous tail vein injection or by peroral gavage to groups of three 18-22 g female BALB/c mice. BMS-345541 is formulated as a 2 mg/mL solution in 3% Tween 80, water. Mice receive either a 2 mg/kg (1 mL/kg) intravenous bolus or a 10 mg/kg (5 mL/kg) peroral gavage. Whole blood samples are taken from individual mice by orbital bleed and cardiac puncture at 0, 0.05, 0.25, 0.5, 1.0, 3.0, 6.0, and 8.0 h after dosing. Whole blood is centrifuged at 20×10 <sup>3</sup> ×g for 5 min. Serum is stored at -20°C until analysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### CUSTOMER VALIDATION

- Cancer Cell. 2015 Mar 9;27(3):409-25.
- Cell Res. 2019 Mar;29(3):193-205.
- Nat Metab. 2023 Mar 6.

- Sci Transl Med. 2021 Jan 27;13(578):eaba7308.
- Cell Syst. 2018 Apr 25;6(4):424-443.e7.

See more customer validations on www.MedChemExpress.com

#### REFERENCES

[1]. Burke JR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem, 2003, 278(3), 1450-1456.

[2]. Yang J, et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res, 2006, 12(3 Pt 1), 950-960.

[3]. MacMaster JF, et al. An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res, 2003, 52(12), 508-511.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA